

(PS2335) PD-1AB21-EXPRESSING, ANTI-CD19 CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY

Topic: 26. Gene therapy, cellular immunotherapy and vaccination - Clinical

Bo Peng^{*1}, Liping Dou², Dai-Hong Liu²

¹Senior Department of Hematology, Chinese PLA General Hospital, Beijing, China; ²The Fifth Medical Center of Chinese PLA General Hospital, Chief Department of Hematology, Beijing, China;

Background

While CD19-directed chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), primary resistance, relapse, and limited response durability remain significant challenges. Strategies to overcome these limitations, including combination with PD-1 blockade, often face issues with systemic toxicity and variable efficacy.

Aims

We aimed to assess the safety, feasibility, and preliminary efficacy of a novel CD19-directed CAR T-cell product engineered to express a bifunctional fusion protein targeting PD-1 and interleukin-21 (PD-1Ab21-CD19 CAR-T) in patients with R/R DLBCL.

Methods

In this open-label, single-arm, phase I trial, patients (aged 14–75 years) with CD19-positive R/R DLBCL received lymphodepletion with fludarabine/cyclophosphamide, followed by a single infusion of PD-1Ab21-CD19 CAR-T cells at doses of 0.3, 1, 3, or 9×10⁶ cells/kg. The primary endpoint was the safety and feasibility of PD-1Ab21-CD19 CAR-T cell. Secondary endpoints included efficacy, CAR-T persistence, progression-free survival (PFS), and overall survival (OS).

Results

Between November 2022 and October 2024, 14 patients received PD-1Ab21-CD19 CAR-T cell infusion. Cytokine release syndrome (CRS) occurred in 11 patients (78.6%; grade 3: 7.1%), with a median onset of 10 days. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 1 patient (grade 3, 7.1%). No treatment-related mortality or unexpected immune-related adverse events were observed. The overall response rate was 71.4%, with 57.1% achieving complete metabolic remission. At a median follow-up of 22.2 months, the 6-month PFS and OS rates were 64.3% and 71.4%, respectively (Figure 1).

Figure 1. Response of R/R DLBCL patients treated with PD-1Ab21-CD19CAR-T. a. Individual patient swimmer plots and their response to PD-1Ab21-CD19CAR-T over time. b. PET/CT scans of patient 3 before and 1 month after PD-1Ab21-CD19CAR-T infusion, demonstrating CMR. c. Overall survival in patients treated with PD-1Ab21-CD19CAR-T. d. Progression-free survival in patients treated with PD-1Ab21-CD19CAR-T.


Summary/Conclusion

PD-1Ab21-CD19 CAR-T therapy demonstrated a manageable safety profile and promising antitumor activity in patients with heavily pretreated R/R DLBCL. The localized delivery of PD-1 blockade and IL-21 via engineered CAR-T cells may mitigate systemic toxicity while enhancing efficacy. These findings warrant further in

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.



Copyright Information: (Online) ISSN: 2572-9241
©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.
Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.